skip to content

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

  •   Table of Contents

Download Guidelines

Entry Inhibitors

Maraviroc (Selzentry, MVC)

Last Updated: October 26, 2016; Last Reviewed: October 26, 2016

Maraviroc is classified as Food and Drug Administration Pregnancy Category B.1

Animal Studies

Maraviroc was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests. Long-term animal carcinogenicity studies of maraviroc showed no drug-related increases in tumor incidence.

Reproductive toxicity has been evaluated in rats and rabbits. Maraviroc produced no adverse effects on fertility of male or female rats at doses with exposures (area under the curve [AUC]) up to 20-fold higher than in humans given the recommended 300-mg, twice-daily dose.

Teratogenicity/Developmental Toxicity
The incidence of fetal variations and malformations was not increased in embryo-fetal toxicity studies in rats at AUC approximately 20-fold higher (and in rabbits at approximately 5-fold higher) than human exposures at the recommended 300-mg, twice-daily dose (up to 1000 mg/kg/day in rats and 75 mg/kg/day in rabbits).

Placental and Breast Milk Passage
Minimal placental passage was demonstrated in a study of single-dose maraviroc in rhesus macaques that showed poor placental transfer and rapid clearance from infant monkeys’ blood.2 Studies in lactating rats indicate that maraviroc is extensively secreted into rat milk.1

Human Studies in Pregnancy

A U.S./European study of intensive, steady-state 12-hour pharmacokinetic profiles in the third trimester and at least 2 weeks postpartum included 18 women taking maraviroc as part of clinical care.3 Sixty-seven percent were taking 150 mg BID with a protease inhibitor; 11% took 300 mg BID and 22% took an alternative regimen. The geometric mean ratios for third-trimester versus postpartum AUC were 0.72 and 0.70 for maximum maraviroc concentration. Despite the overall 30% decrease in maraviroc exposure during pregnancy and 15% decrease in Ctrough, Ctrough exceeded the minimum target concentration of 50 ng/mL, and only one woman had a Ctrough below that level both during pregnancy and post-partum. These data suggest that the standard adult dose adjusted for concomitant antiretroviral (ARV) drugs seems appropriate in pregnancy. A review of drug interactions between ARV drugs and oral contraceptives found that it is safe to coadminister oral contraceptives with maraviroc.4

Other Safety Issues
A retrospective study from an English-Irish cohort of 857 pregnant women showed an increased rate of hepatotoxicity among the 492 who started antiretroviral therapy during pregnancy.5 Maraviroc was one of three drugs that was associated with an increased risk of liver enzyme elevation during pregnancy with an aHR of 4.19 [1.34–13.1, P = 0.01], along with efavirenz and nevirapine. In a model using human placental BeWo cells, maraviroc inhibited transplacental passage of two fluorescent organic cations, suggesting that it might influence placental drug transfer and cause drug-drug interactions.6

Placental and Breast Milk Passage
An ex vivo human placental cotyledon perfusion model demonstrated minimal placental passage of maraviroc.7 In a study in humans of 6 mother/infant pairs, the median ratio of cord blood-to-maternal-plasma drug concentrations was 0.33 (0.03–0.56).3,8 Whether maraviroc is secreted into human milk is unknown.

Teratogenicity/Developmental Toxicity
In the Antiretroviral Pregnancy Registry, insufficient numbers of first-trimester exposures to maraviroc in humans have been monitored to be able to make a risk determination.9,10

Excerpt from Table 8a
Generic Name
Trade Name
Formulation Dosing Recommendations Use in Pregnancy
  • 150 mg
  • 300 mg
Standard Adult Dose:
  • 300 mg twice daily with or without food
  • MVC must be used in combination with other ARVs in HIV-1-infected adults with only CCR5-tropic virus.
Dose Adjustments:
  • Increase to 600 mg BID when used with potent CYP3A inducers: EFV, ETR, and rifampin.
  • Decrease to 150 mg BID when used with CYP3A inhibitors: all PIs except TPV/r and itraconazole.
PK in Pregnancy:
  • A PK study in human pregnancy demonstrated a 20% to 30% overall decrease in AUC, but Ctrough exceeded the recommended minimal concentration of 50 ng/mL.
Dosing in Pregnancy:
  • Standard adult dosing adjusted for concomitant ARV use appears appropriate.
No evidence of teratogenicity in rats or rabbits; insufficient data to assess for teratogenicity in humans.

MVC placental passage category should be moderate.b

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:
     High: >0.6
     Moderate: 0.3–0.6
     Low: <0.3

Key to Abbreviations: ARV = antiretroviral; AUC = area under the curve; BID = twice daily; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; PI = protease inhibitor; PK = pharmacokinetic


  1. Maraviroc [package insert]. Food and Drug Administration. 2015. Available at Accessed July 18, 2016.
  2. Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother. 2010;54(10):4059-4063. Available at
  3. Colbers A, Best B, Schalkwijk S, et al. Maraviroc pharmacokinetics in HIV-1-infected pregnant women. Clin Infect Dis. 2015;61(10):1582-1589. Available at
  4. Tittle V, Bull L, Boffito M, Nwokolo N. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. Clin Pharmacokinet. 2015;54(1):23-34. Available at
  5. Huntington S, Thorne C, Anderson J, et al. Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women? J Int AIDS Soc. 2014;17(4 Suppl 3):19486. Available at
  6. Nabekura T, Kawasaki T, Kamiya Y, Uwai Y. Effects of antiviral drugs on organic anion transport in human placental BeWo cells. Antimicrob Agents Chemother. 2015;59(12):7666-7670. Available at
  7. Vinot C, Gavard L, Treluyer JM, et al. Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob Agents Chemother. 2013;57(3):1415-1420. Available at
  8. Colbers A, Best B, al e. A Comparison of the Pharmacokinetics of Maraviroc during Pregnancy and Postpartum. Abstract 931. 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013, 2013; Atlanta, GA.
  9. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989–31 July 2015. Wilmington, NC: Registry Coordinating Center. 2015. Available at
  10. Floridia M, Mastroiacovo P, Tamburrini E, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001–2011. BJOG. 2013;120(12):1466-1475. Available at

Download Guidelines